This bill directs the Secretary of Health and Human Services to withdraw the current REMS (risk evaluation and mitigation strategy) for mifepristone and, within 90 days of enactment, re‑approve a REMS identical to the version the Secretary approved in June 2011. It bars the Secretary from approving any REMS for mifepristone that differs from that 2011 strategy.
The bill also creates a federal private right of action against “covered entities” (telehealth providers, pharmacies, or anyone who knowingly imports or transports mifepristone in violation of 18 U.S.C. 1462), authorizing compensatory and punitive damages plus attorneys’ fees, and amends the Federal Food, Drug, and Cosmetic Act to prohibit importation of mifepristone into the United States, including by mail. The combination of a frozen REMS, an import ban, and a broad federal tort would reshape how mifepristone is prescribed, dispensed, and litigated in the U.S.
At a Glance
What It Does
The bill requires HHS to reinstate a REMS for mifepristone identical to the June 2011 REMS within 90 days and forbids any different REMS. It creates a federal cause of action against telehealth providers, pharmacies, and others who knowingly import or transport mifepristone in violation of federal law, and amends the FD&C Act to bar importation, including by mail.
Who It Affects
Hospitals, clinicians, pharmacies that dispense mifepristone, telehealth services that prescribe or facilitate receipt of the drug, importers and carriers, civil plaintiffs and defense counsel, and federal agencies responsible for drug regulation and customs enforcement.
Why It Matters
The bill removes agency discretion to modify REMS based on new data, criminalizes and civilly penalizes cross‑border supply routes, and adds high‑stakes litigation risk for providers and pharmacies — a regulatory package likely to narrow access and trigger enforcement and administrative challenges.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill starts by defining the covered medication narrowly as mifepristone (identified by brand and code names). Its core administrative command directs the Secretary of Health and Human Services to withdraw any current REMS in effect at enactment and to adopt, within 90 days, a REMS that matches exactly the REMS the agency approved in June 2011.
The statute then bars the Secretary from approving any alternative REMS for mifepristone, effectively locking the agency into the earlier risk‑management design regardless of subsequent evidence or policy changes.
Separately, the bill establishes a federal civil remedy for people who suffer bodily injury or mental‑health harms “attributable, in whole or in part,” to their use of mifepristone when the drug was imported or transported in interstate or foreign commerce in violation of 18 U.S.C. 1462. It defines covered entities to include telehealth providers and pharmacies and permits plaintiffs to sue in federal or state court for compensatory and punitive damages plus attorneys’ fees and costs.
The text preserves state law remedies, so this federal cause of action does not displace other state claims.Finally, the bill amends the Federal Food, Drug, and Cosmetic Act to add mifepristone to the set of drugs that may not be imported into the United States and expressly bars mailing the drug into the country. Taken together, these provisions constrain regulatory flexibility at HHS, cut off an importation pathway, and create a new civil exposure for certain providers and distributors tied to imported or illegally transported mifepristone.
The Five Things You Need to Know
The bill requires HHS to withdraw the REMS in effect at enactment and, within 90 days, approve a REMS identical to the one the agency approved in June 2011.
It prohibits the Secretary from approving any REMS for mifepristone that differs from the June 2011 strategy.
Section 4 creates a federal private right of action against telehealth providers, pharmacies, or any person who knowingly imports or transports mifepristone in violation of 18 U.S.C. 1462, allowing compensatory damages, punitive damages, and attorneys’ fees.
Section 4 takes effect 90 days after enactment for the private‑action provision; the REMS directive requires agency action within 90 days of enactment.
The bill amends 21 U.S.C. 381 to ban importation of mifepristone into the United States and expressly bars mailing the drug into the country.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Establishes the Act’s name as the “Restoring Safeguards for Dangerous Abortion Drugs Act.” This is a technical caption but signals the bill’s intent to treat mifepristone as a uniquely regulated product for the purposes that follow.
Definition of covered medication
Defines “covered medication” narrowly as mifepristone and lists the brand and developmental names used in commerce. That definition scopes every operative obligation and prohibition in the bill to this single active ingredient, rather than to combination regimens or other drugs used in abortion care.
REMS—withdrawal and reinstatement of June 2011 strategy
Directs the HHS Secretary to withdraw any REMS in effect at enactment and to approve, within 90 days, a REMS identical to the June 2011 REMS. It adds a statutory restriction that the Secretary must require a REMS for mifepristone and may not approve a different REMS. Practically, this removes the agency’s discretion to adapt the REMS for mifepristone to new safety data or implementation experience until Congress changes the statute.
Federal tort for harms from imported/transported mifepristone
Creates a federal cause of action for individuals who suffer bodily injury or mental‑health harms attributable to their use of mifepristone when that drug was imported or transported in violation of 18 U.S.C. 1462. The provision defines covered entities (telehealth providers, pharmacies, and others who knowingly import/transport in violation of the cited criminal statute) and authorizes compensatory and punitive damages plus attorneys’ fees. The section also preserves state‑law remedies, allowing parallel state claims; it takes effect 90 days after enactment for affected parties to bring suit.
Ban on importation and mailing of mifepristone
Amends FD&C Act §801 to add an explicit prohibition on importing mifepristone into the United States and makes clear that the ban includes mailing the drug to individuals. This turns a statutory restriction into an affirmative import bar, implicating customs, postal controls, and other enforcement tools available to federal agencies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Plaintiffs alleging harm from imported mifepristone: the bill creates a new federal cause of action that allows compensatory and punitive damages plus attorneys’ fees, improving remedies and forum options for alleged victims.
- Domestic manufacturers or distributors of regulated drugs: by banning imports and freezing REMS requirements, the bill may reduce competition from foreign‑sourced mifepristone and reinforce control by U.S. supply‑chain actors who comply with the reinstated REMS.
- Plaintiff trial lawyers and firms that litigate pharmaceutical torts: the statutory right to punitive damages and fee shifting makes certain case types more commercially attractive to pursue.
Who Bears the Cost
- Telehealth providers and pharmacies: the bill exposes these providers to federal civil liability (including punitive damages and fees) if they are found to have imported or transported mifepristone in violation of 18 U.S.C. 1462, creating legal and compliance risk that could chill prescribing and dispensing practices.
- Importers, carriers, and individuals who ship mifepristone: the FD&C Act amendment flatly forbids importation and mailing of mifepristone, removing a cross‑border supply route and increasing seizure and enforcement risk for shipments.
- HHS/FDA and enforcement agencies: the bill constrains FDA’s discretion over REMS design by statute and directs agency action on a 90‑day clock, while also creating an enforcement obligation for customs, postal authorities, and federal prosecutors to prevent and police importation.
Key Issues
The Core Tension
The statute pits two legitimate objectives against one another: protecting patients by reinstating stricter, court‑enforceable controls on a single drug versus preserving regulatory flexibility, evidence‑based updates, and access to care. Achieving one objective—tighter, criminally and civilly enforceable limits—necessarily curtails the other: the agency’s ability to adapt risk management to evolving science and the ability of providers and pharmacies to supply medication without heightened litigation risk.
The bill freezes a specific regulatory design (the June 2011 REMS) into statute and forbids any different REMS for mifepristone. That approach resolves regulatory uncertainty by prescription, but it also removes the agency’s ability to reevaluate and modernize risk‑mitigation measures in light of new evidence, changes in clinical practice, or implementation problems.
Freezing an earlier REMS may produce mismatches between statutory requirements and current clinical standards, supply‑chain realities, or patient needs.
The private‑action and import ban components create enforcement and compliance tensions. The federal cause of action targets harms tied to imported or unlawfully transported mifepristone, but the bill does not define how causation will be demonstrated in practice (for example, how a plaintiff will prove the drug was imported in violation of 18 U.S.C. 1462, or that a specific provider’s conduct caused the alleged physical or mental‑health harm).
Allowing punitive damages and fee shifting raises the stakes for defendants and may produce defensive behavior—reduced telehealth prescribing or tighter pharmacy controls—that affects access. The import ban will require coordination among FDA, DHS, USPS, and private carriers; the bill is silent on operational protocols, exemptions for personal medical importation, or administrative adjudication processes for seized shipments.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.